{
  "id": "breast-biomarker-by-method",
  "display_name": "Breast Cancer Biomarker Testing by Method",
  "cohort": "Breast Cancer Biomarker Testing, by Method (2024–2025)",
  "insight_type": "Precision Medicine Utilization",
  "summary": "Standard breast cancer testing methods (IHC for ER/PR/HER2) are at >95% compliance, but advanced methods like NGS (62%) and RNA-seq (36%) lag significantly. This gap represents a $165,000 opportunity.",
  "chart": {
    "type": "bar",
    "unit": "method",
    "data": [
      { "name": "IHC (ER/PR)", "value": 98, "gap": 8, "highlight": false },
      { "name": "IHC (HER2)", "value": 95, "gap": 5, "highlight": false },
      { "name": "FISH (HER2)", "value": 92, "gap": 2, "highlight": false },
      { "name": "PCR (gene-specific)", "value": 75, "gap": -15, "highlight": false },
      { "name": "NGS Panel", "value": 62, "gap": -28, "highlight": true },
      { "name": "RNA-seq", "value": 36, "gap": -54, "highlight": true }
    ],
    "benchmark": 90,
    "nccn_target": 95
  },
  "financial_impact": {
    "annual_opportunity": "$165,000/year",
    "math": "$165,000/year = 28% testing gap (NGS) × 22 metastatic breast cancer patients × $27,000 improved therapy matching"
  },
  "clinical_impact": {
    "description": "Expanded molecular testing in breast cancer improves identification of targetable alterations and therapy selection.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+6.1 months",
        "description": "Improved progression-free survival with NGS-guided therapy"
      },
      {
        "type": "OS",
        "value": "+7.8 months",
        "description": "Overall survival benefit with comprehensive testing"
      },
      {
        "type": "ORR",
        "value": "+32%",
        "description": "Higher objective response rate with matched therapies"
      },
      {
        "type": "CT",
        "value": "+47%",
        "description": "Increased clinical trial eligibility identification"
      },
      {
        "type": "AEs",
        "value": "-28%",
        "description": "Reduced adverse events with optimized treatment selection"
      }
    ],
    "quantitative": "+7.8 months OS"
  },
  "peer_comparison": {
    "description": "Leading breast cancer programs utilize NGS panel testing in >85% of metastatic cases, vs. your 62%, identifying more actionable alterations.",
    "peer_benchmark": 85,
    "financial_impact": {
      "annual_opportunity": "$185,000/year",
      "math": "$185,000/year = 23% gap to peer benchmark × 30 patients × $26,800 improved care value"
    },
    "action_steps": [
      {
        "text": "Implement NGS-first reflex testing protocol for metastatic breast cancer",
        "icon": "document"
      },
      {
        "text": "Create standardized PIK3CA testing pathway for HR+/HER2- cases",
        "icon": "flask"
      },
      {
        "text": "Develop BRCA1/2 testing implementation strategy",
        "icon": "cog"
      },
      {
        "text": "Establish molecular tumor board for complex cases",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 92,
  "action_steps": [
    {
      "text": "Implement universal NGS panel for all metastatic breast cancer",
      "icon": "document"
    },
    {
      "text": "Create PIK3CA testing protocol in HR+/HER2- disease",
      "icon": "clipboard"
    },
    {
      "text": "Develop BRCA testing pathway for high-risk patients",
      "icon": "flask"
    },
    {
      "text": "Establish testing method tracking dashboard",
      "icon": "chart"
    }
  ],
  "suggestions": [
    {
      "text": "Consider HRD testing implementation for TNBC/BRCA+ cases",
      "icon": "lightbulb"
    },
    {
      "text": "Evaluate germline/somatic testing combination strategy",
      "icon": "search"
    }
  ],
  "drilldowns": [
    {
      "label": "By Provider",
      "cohort": "Breast Cancer Testing by Provider",
      "jsonFile": "breast-biomarker-by-provider.json",
      "drilldownLevel": 3
    },
    {
      "label": "All Breast Biomarkers",
      "cohort": "Breast Cancer Biomarker Testing",
      "jsonFile": "breast-biomarker.json",
      "drilldownLevel": 2
    },
    {
      "label": "All Methods",
      "cohort": "Biomarker Testing by Method",
      "jsonFile": "biomarker-compliance-by-method.json",
      "drilldownLevel": 1
    },
    {
      "label": "Overall Compliance",
      "cohort": "Biomarker Testing Compliance",
      "jsonFile": "biomarker-compliance.json",
      "drilldownLevel": 0
    }
  ]
} 